Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q3 FY19 results · Oct–Dec 2018
Bliss GVS Pharma reported revenue from operations of ₹220.43 crore and net profit of ₹27.23 crore for Q3 FY19 (Oct–Dec 2018), on a consolidated basis.
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 220.43 | — | — | 228.43 | −3.5% |
| Other income | (3.90) | — | — | 24.87 | Turned loss |
| Total income | 216.53 | — | — | 253.31 | −14.5% |
| Profit before tax | 36.48 | — | — | 62.79 | −41.9% |
| Net profit for the period | 27.23 | — | — | 41.67 | −34.6% |
| Attributable to shareholders of the company | 25.84 | — | — | 41.46 | −37.7% |
| EPS, basic (₹) | 2.50 | — | — | 4.02 | −37.8% |
| Net margin (%) | 12.4 | — | 18.2 |
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 95.63 | — | — | 119.97 | −20.3% |
| Other income | (4.35) | — | — | 24.01 | Turned loss |
| Total income | 91.28 | — | — | 143.98 | −36.6% |
| Profit before tax | 18.27 | — | — | 49.20 | −62.9% |
| Net profit for the period | 11.70 | — | — | 31.05 | −62.3% |
| EPS, basic (₹) | 1.13 | — | — | 3.01 | −62.5% |
| Net margin (%) | 12.2 | — | 25.9 |
Consolidated
- Filed with BSE
- 31 Jan 2019, 14:27 IST
- Board meeting
- 29 Jan 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 Jan 2019, 14:27 IST
- Board meeting
- 29 Jan 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE